Bookmark us
 
 
 

 

ZytuxTM is a biosimilar product with the generic name of Rituximab and is used for treatment of some types of cancer. It is a chimeric monoclonal antibody against CD20 antigens presents on surface of lymphocyte cells.


ZytuxTMis a genetically engineered human-mouse chimeric monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells in suspension and purified by some steps of chromatography. It is a fusion of the light and heavy chain variable domains of a murine monoclonal anti-CD20 antibody and human kappa light-chain and gamma 1 heavy-chain constant regions. Active ingredient of Zytux™, Rituximab, consists of two heavy chains of 451 amino acids and two light chains of 213 amino acids, with an approximate molecular weight of 148 kDa. Rituximab binds to the target CD20 antigen via the variable murine regions, while the remainder of the antibody interacts with human immune-effector mechanisms to kill the target cells.


ZytuxTM is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) infusion. It is provided in two dosages, 100 mg and 500 mg vials.

 

For more information visit us  at  www.zytux.com

   
       
 

Aryogen staff are happy with their job supporting advanced production systems and their needs.



Download Leaflet of ZytuxTM


Download HCP of ZytuxTM